Nuclear transport modulators and uses thereof
View Patent ↗The invention generally relates to the field of nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to new substituted-heterocyclic azole compounds, the synthesis and use of these compounds and their pharmaceutical compositions, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity such as in treating cancer and other neoplastic disorders, inflammatory diseases, disorders of abnormal tissue growth and fibrosis including cardiomyopathy, pulmonary fibrosis, hepatic fibrosis, glomerulonephritis, and other renal disorders, and for the treatment of viral infections (both acute and chronic).
1. A method for modulating CRM1, comprising contacting CRM1 with a therapeutically effective amount of a compound of formula III′:
or a pharmaceutically acceptable salt thereof, wherein:
A′ is phenyl substituted with one or more R 1′ ;
each R 1′ is independently selected from the group consisting of halogen, —NO 2 , —CN, —OR a , —SR a , —N(R a ) 2 , —N 3 , or -L 1 -R;
each R a is independently —H, —R or —C(O)R;
L 1 is a covalent bond or an optionally substituted bivalent C 1-6 hydrocarbon chain, wherein one or more methylene units of L 1 is optionally and independently replaced by -Cy-, —O—, —S—, —N(R a )—, —C(O)—, —C(S)—, —C(O)N(R a )—, —N(R a )C(O)N(R a )—, —N(R a )C(O)—, —N(R a )C(O)O—, —OC(O)N(R a )—, —S(O)—, —S(O) 2 —, —S(O) 2 N(R a )—, —N(R a )S(O) 2 —, —OC(O)—, or —C(O)O—;
-Cy- is an optionally substituted bivalent ring selected from a 3-7 membered saturated or partially unsaturated cycloalkylene ring, a 4-7 membered saturated or partially unsaturated heterocycloalkylene ring having 1-4 heteroatoms independently selected from nitrogen, oxygen and sulful, phenylene, a 5-6 membered monocyclic heteroarylene having 1-3 heteroatoms independently selected from nitrogen, oxygen and sulfur, an 8-10 membered bicyclic arylene, or an 8-10 membered bicyclic heteroarylene having 1-4 heteroatoms independently selected from nitrogen, oxygen and sulfur;
each R is independently optionally substituted C 1-8 alkyl; C 2-8 alkenyl; C 2-8 alkynyl; haloalkyl; phenyl; a 3-7 membered saturated or partially unsaturated cycloalkyl ring; an 8-10 membered bicyclic saturated, partially unsaturated or aryl carbocyclic ring; a 4-7 membered saturated or partially unsaturated heterocycloalkyl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5-6 membered monocyclic heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or:
two R on the same nitrogen are taken together with their intervening atoms to form a 4-7 membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen and sulfur; and
R 3′ is -L 1′ -R′ wherein L 1′ is —CH 2 — and R′ is a 5-6 membered monocyclic heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen and sulfur.
2. The method according to claim 1 , wherein R 3′ is -L 1′ -R′, wherein L 1′ is —CH 2 — and R′ is a 6-membered monocyclic heterocyclic ring having 1-3 nitrogens.
3. The method according to claim 1 , wherein the compound is selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.
4. The method according to claim 1 , wherein the compound of formula III′ or the pharmaceutically acceptable salt thereof inhibits CRM1.
5. The method according to claim 1 , wherein contacting CRM1 with a therapeutically effective amount of a compound of formula III′ or a pharmaceutically acceptable salt thereof comprises administering to an isolated tissue or a cell a therapeutically effective amount of the compound of formula III′ or pharmaceutically acceptable salt thereof.
6. The method according to claim 5 , wherein the compound of formula III′ or pharmaceutically acceptable salt thereof is administered to a cell in vitro.
7. The method according to claim 5 , wherein the compound of formula III′ or pharmaceutically acceptable salt thereof is administered to a cell ex vivo.
8. The method according to claim 5 , wherein the isolated tissue or the cell is from a subject having a CRM1-mediated disorder.
9. The method according to claim 8 , wherein the CRM1-mediated disorder is cancer.
10. A method for modulating CRM1, comprising contacting CRM1 with a therapeutically effective amount of a compound of formula III′:
or a pharmaceutically acceptable salt thereof, wherein:
A′ is phenyl substituted with one or more R 1′ ;
each R 1′ is independently selected from the group consisting of halogen, —NO 2 , —CN, —OR a , —SR a , —N(R a ) 2 , —N 3 , or -L 1 -R;
each R a is independently —H, —R or —C(O)R;
L 1 is a covalent bond or an optionally substituted bivalent C 1-6 hydrocarbon chain, wherein one or more methylene units of L 1 is optionally and independently replaced by -Cy-, —O—, —S—, —N(R a )—, —C(O)—, —C(S)—, —C(O)N(R a )—, —N(R a )C(O)N(R a )—, —N(R a )C(O)—, —N(R a )C(O)O—, —OC(O)N(R a )—, —S(O)—, —S(O) 2 —, —S(O) 2 N(R a )—, —N(R a )S(O) 2 —, —OC(O)—, or —C(O)O—;
-Cy- is an optionally substituted bivalent ring selected from a 3-7 membered saturated or partially unsaturated cycloalkylene ring, a 4-7 membered saturated or partially unsaturated heterocycloalkylene ring having 1-4 heteroatoms independently selected from nitrogen, oxygen and sulful, phenylene, a 5-6 membered monocyclic heteroarylene having 1-3 heteroatoms independently selected from nitrogen, oxygen and sulfur, an 8-10 membered bicyclic arylene, or an 8-10 membered bicyclic heteroarylene having 1-4 heteroatoms independently selected from nitrogen, oxygen and sulfur;
each R is independently optionally substituted C 1-8 alkyl; C 2-8 alkenyl; C 2-8 alkynyl; haloalkyl; phenyl; 3-7 membered saturated or partially unsaturated cycloalkyl ring; 8-10 membered bicyclic saturated, partially unsaturated or aryl carbocyclic ring; 4-7 membered saturated or partially unsaturated heterocycloalkyl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; 5-6 membered monocyclic heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or:
two R on the same nitrogen are taken together with their intervening atoms to form a 4-7 membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen and sulfur; and
R 3′ is —CH(CH 3 ) 2 .
11. The method according to claim 10 , wherein the compound is selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.
12. The method according to claim 11 , wherein the compound is selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.
13. The method according to claim 10 , wherein the compound of formula III′ or the pharmaceutically acceptable salt thereof inhibits CRM1.
14. The method according to claim 10 , wherein contacting CRM1 with a therapeutically effective amount of a compound of formula III′ or a pharmaceutically acceptable salt thereof comprises administering to an isolated tissue or a cell a therapeutically effective amount of the compound of formula III′ or pharmaceutically acceptable salt thereof.
15. The method according to claim 14 , wherein the compound of formula III′ or pharmaceutically acceptable salt thereof is administered to a cell in vitro.
16. The method according to claim 14 , wherein the compound of formula III′ or pharmaceutically acceptable salt thereof is administered to a cell ex vivo.
17. The method according to claim 14 , wherein the isolated tissue or the cell is from a subject having a CRM1-mediated disorder.
18. The method according to claim 17 , wherein the CRM1-mediated disorder is cancer.
19. A method for modulating CRM1, comprising contacting CRM1 with a therapeutically effective amount of a compound selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.
20. The method according to claim 19 , wherein the compound or the pharmaceutically acceptable salt thereof inhibits CRM1.
21. The method according to claim 19 , wherein contacting CRM1 with a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof comprises administering to an isolated tissue or a cell a therapeutically effective amount of the compound or pharmaceutically acceptable salt thereof.
22. The method according to claim 21 , wherein the compound of formula III′ or pharmaceutically acceptable salt thereof is administered to a cell in vitro.
23. The method according to claim 21 , wherein the compound of formula III′ or pharmaceutically acceptable salt thereof is administered to a cell ex vivo.
24. The method according to claim 21 , wherein the isolated tissue or the cell is from a subject having a CRM1-mediated disorder.
25. The method according to claim 24 , wherein the CRM1-mediated disorder is cancer.